Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (91-100 of 212) with videos related to

Pageof 22
Sort By:
Journal for Immunotherapy of Cancer|June 19, 2015
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanomaMichael A Postow, Manuarii Manuel, Phillip Wong, et al.
Journal of the American Academy of Dermatology|March 21, 2021
Dermatologic infections in cancer patients treated with checkpoint inhibitorsMytrang H Do, Dulce M Barrios, Gregory S Phillips, et al.
Revista Da Associacao Medica Brasileira (1992)|December 15, 2017
Treatment of advanced melanoma - A changing landscapeAdriana Hepner, Alessandra Salgues, Carlos A Dos Anjos, et al.
Journal of Translational Medicine|April 22, 2022
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, et al.
Journal for Immunotherapy of Cancer|October 21, 2018
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer StatementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 8, 2020
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic LeukemiaJames W Smithy, Matthew J Pianko, Colleen Maher, et al.
Journal for Immunotherapy of Cancer|March 11, 2020
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitorsMaha Mamoor, Michael A Postow, Jessica A Lavery, et al.
Pigment Cell & Melanoma Research|April 11, 2023
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, et al.
Nature Communications|July 18, 2025
Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysisXiyu Peng, James W Smithy, Mohammad Yosofvand, et al.
Pageof 22

Showing results (91-100 of 212) with videos related to

Sort By:
Pageof 22
Journal for Immunotherapy of Cancer|June 19, 2015
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanomaMichael A Postow, Manuarii Manuel, Phillip Wong, et al.
Journal of the American Academy of Dermatology|March 21, 2021
Dermatologic infections in cancer patients treated with checkpoint inhibitorsMytrang H Do, Dulce M Barrios, Gregory S Phillips, et al.
Revista Da Associacao Medica Brasileira (1992)|December 15, 2017
Treatment of advanced melanoma - A changing landscapeAdriana Hepner, Alessandra Salgues, Carlos A Dos Anjos, et al.
Journal of Translational Medicine|April 22, 2022
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, et al.
Journal for Immunotherapy of Cancer|October 21, 2018
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer StatementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 8, 2020
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic LeukemiaJames W Smithy, Matthew J Pianko, Colleen Maher, et al.
Journal for Immunotherapy of Cancer|March 11, 2020
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitorsMaha Mamoor, Michael A Postow, Jessica A Lavery, et al.
Pigment Cell & Melanoma Research|April 11, 2023
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, et al.
Nature Communications|July 18, 2025
Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysisXiyu Peng, James W Smithy, Mohammad Yosofvand, et al.
Pageof 22